Cargando…

COVID-19 vaccines and multiple sclerosis disease-modifying therapies

Detalles Bibliográficos
Autores principales:	Giovannoni, Gavin, Hawkes, Christopher H., Lechner-Scott, Jeannette, Levy, Michael, Yeh, E. Ann, Baker, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286545/ https://www.ncbi.nlm.nih.gov/pubmed/34358943 http://dx.doi.org/10.1016/j.msard.2021.103155

Ejemplares similares

Vaccine hesitancy in people with multiple sclerosis
por: Lechner-Scott, Jeannette S, et al.
Publicado: (2022)

Is multiple sclerosis a risk factor for infections?
por: Lechner-Scott, Jeannette, et al.
Publicado: (2020)

The COVID-19 pandemic and the use of MS disease-modifying therapies
por: Giovannoni, Gavin, et al.
Publicado: (2020)

Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis
por: Salama, Sara, et al.
Publicado: (2020)

B cell therapy and the use of RNA-based COVID-19 vaccines
por: Vishnevetsky, Anastasia, et al.
Publicado: (2021)

Long COVID or post COVID-19 syndrome
por: Lechner-Scott, J., et al.
Publicado: (2021)

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
por: Baker, David, et al.
Publicado: (2020)

How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?
por: Giovannoni, Gavin
Publicado: (2022)

Multiple Sclerosis Cerebrospinal Fluid Biomarkers
por: Giovannoni, Gavin
Publicado: (2006)

Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19
por: Giovannoni, Gavin
Publicado: (2020)

Multiple Sclerosis and Its Treatment
por: Giovannoni, Gavin, et al.
Publicado: (1999)

Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis
por: Beard, Katherine, et al.
Publicado: (2021)

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2021)

COVID‐19 Vaccine Response in People with Multiple Sclerosis
por: Tallantyre, Emma C., et al.
Publicado: (2021)

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

The Potential for EBV Vaccines to Prevent Multiple Sclerosis
por: Maple, Peter A., et al.
Publicado: (2022)

The effect of cladribine on immunoglobulin levels compared to B cell targeting therapies in multiple sclerosis
por: Lycett, Mitchell J, et al.
Publicado: (2023)

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis
por: Allen-Philbey, K., et al.
Publicado: (2022)

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis
por: Tallantyre, Emma C, et al.
Publicado: (2022)

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis
por: Xavier, Alexandre, et al.
Publicado: (2023)

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
por: Baker, David, et al.
Publicado: (2017)

Erythrocytes in multiple sclerosis – forgotten contributors to the pathophysiology?
por: Groen, Kira, et al.
Publicado: (2016)

Multiple Sclerosis, Viruses, and New Vaccines
por: Maple, Peter A. C.
Publicado: (2021)

Neuroprotection in a Novel Mouse Model of Multiple Sclerosis
por: Lidster, Katie, et al.
Publicado: (2013)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Predicting Multiple Sclerosis: Challenges and Opportunities
por: Hone, Luke, et al.
Publicado: (2022)

Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies
por: Baba, Cavid, et al.
Publicado: (2022)

WITHDRAWN: Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity
por: Kim, Enoch, et al.
Publicado: (2022)

Fast magnetic resonance spectroscopic imaging techniques in human brain- applications in multiple sclerosis
por: Al-iedani, Oun, et al.
Publicado: (2017)

The Multiple Sclerosis Care Unit
por: Soelberg Sorensen, Per, et al.
Publicado: (2018)

Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects
por: Chun, Jerold, et al.
Publicado: (2020)

Disease modifying therapies and infection risks in multiple sclerosis—a decision-making conundrum
por: Yong, Kok Pin, et al.
Publicado: (2020)

Personalized Diagnosis and Therapy for Multiple Sclerosis
por: Ramo-Tello, Cristina
Publicado: (2022)

Response of the multiple sclerosis community to COVID-19
por: Ciccarelli, Olga, et al.
Publicado: (2020)

Erythrocyte microRNAs show biomarker potential and implicate multiple sclerosis susceptibility genes
por: Groen, Kira, et al.
Publicado: (2020)

Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium Channels
por: Pryce, Gareth, et al.
Publicado: (2023)

Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination
por: Zheng, Crystal, et al.
Publicado: (2020)

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy
por: Reder, Anthony T, et al.
Publicado: (2022)

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
por: Reder, Anthony T., et al.
Publicado: (2021)

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
por: Simpson-Yap, Steve, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k9u103elaaccr26iap61ak65qa